Deze pagina is automatisch vertaald en de nauwkeurigheid van de vertaling kan niet worden gegarandeerd. Raadpleeg de Engelse versie voor een brontekst.

Interventioneel onderzoek naar rokende vermindering van de psychiatrie (TABAPSY)

7 oktober 2026 bijgewerkt door: GCS-CCOMS

Evaluatie van een interventie om roken te verminderen bij gebruikers van geestelijke gezondheidszorg behandeld in ambulante psychiatrie

The smoking rate among people with mental disorders is higher than in the general population. Greater exposure to the harmful effects of tobacco partly explains the major inequality in life expectancy observed among people with mental disorders who, depending on the disorder and the study, live 10 to 25 years less than the general population, a gap mainly due to the occurrence of cardiovascular and respiratory pathologies, notably bronchial cancers. However, tobacco reduction actions specifically targeting these people remain insufficiently developed, particularly in psychiatry where this addiction is often banalized and its treatment neglected.

The objective of this study is to evaluate an intervention ('Tabapsy') co-constructed with mental health services users, mental health professionals, and general practitioners and targeting adult patients followed in ambulatory psychiatry. The main objective is to evaluate the effectiveness of the intervention on short-term smoking cessation (cessation for at least 7 days) among regular smokers at 3 months. Secondary objectives include evaluation of its cost-effectiveness and implementation. To this end, a national cluster-randomized controlled study will be carried out, supplemented by qualitative interviews to study the implementation of the intervention.

Studie Overzicht

Toestand

Werving

Conditie

Interventie / Behandeling

Gedetailleerde beschrijving

The smoking rate among people with mental disorders is higher than in the general population. Greater exposure to the harmful effects of tobacco partly explains the major inequality in life expectancy observed among people with mental disorders who, depending on the disorder and the study, live 10 to 20 years less than the general population, a gap mainly due to the occurrence of cardiovascular and respiratory pathologies, notably bronchial cancers.

While studies found that people under psychiatric care are as motivated as others to stop smoking, the literature also shows that psychiatric care systems tolerate, underestimate and even encourage smoking among users, despite the fact that psychiatric care, whether at hospital or in an ambulatory setting, is conducive to changes in smoking behaviour and to the implementation of a smoking cessation approach, notably because of anti-smoking regulations in hospitals. In addition, withdrawal symptoms is stronger in this population and smoking cessation would therefore need to be adapted.

Against this backdrop, a smoking cessation intervention ('Tabapsy') was co-constructed with the various stakeholders (users with mental disorders, mental health professionals and general practitioners). Its aim is to encourage and support smoking cessation among people with mental disorders followed in ambulatory psychiatry by medical psychological centers (CMP). It consists of two parts: a campaign to promote smoking cessation within the CMP, and the setting up of an intervention to help people stop smoking. The latter comprises of:

  1. A general information meeting, to encourage motivation to start smoking cessation;
  2. An assessment workshop, to evaluate level of dependence using validated tests and establish a personalized cessation program based on the results obtained;
  3. Five thematic workshops to support cessation, covering 1/ nicotine replacement treatments, electronic cigarettes and other drug treatments available for smoking cessation, 2/ emotional management, 3/ weight gain, 4/ physical activities, and 5/ manual occupations;
  4. Peer support groups, based on the sharing of experiences, to encourage mutual aid and solidarity between people with mental disorders who are trying to quit smoking.

The intervention also relies on a facilitator specifically recruited to set up the intervention and run the various workshops in the CMP. It is complemented by a website that will contain all the resources and information presented during the meetings/workshops.

The primary objective of the study is to evaluate the effectiveness of the "Tabapsy" intervention on short-term smoking cessation (cessation for at least 7 days) at 3 months among regular smokers followed by adult psychiatric CMPs. Secondary objectives include assessing its cost-effectiveness and implementation.

A cluster-randomized controlled trial will be carried out to evaluate the intervention. The cluster is the "psychiatric sector", i.e., the public care entity responsible for organizing the mental health care of a population within a pre-specified geographical area (including hospital and ambulatory care) in France. A psychiatric sector may include one or multiple CMPs depending on the size of the population it serves. Psychiatric sectors will be randomized into one of two groups (intervention or usual practice).

It will be supplemented by a qualitative study to study the implementation of the intervention.

All regular smokers (at least one cigarette a day) who agree to participate will be asked to complete questionnaires on a WebApp at inclusion, and again at 3 and 6 months. Additional questionnaires will be available in the intervention group. Questions will focus on user characteristics, tobacco consumption, level of nicotine dependence, motivation to quit, use of cessation aids, level of mental and physical well-being, smoking-related knowledge and representations, and in the intervention group, participation in the intervention and satisfaction.

6,250 participants will be included over 12 months, in 22 participating sectors.

Studietype

Ingrijpend

Inschrijving (Geschat)

6500

Fase

  • Niet toepasbaar

Contacten en locaties

In dit gedeelte vindt u de contactgegevens van degenen die het onderzoek uitvoeren en informatie over waar dit onderzoek wordt uitgevoerd.

Studiecontact

Studie Locaties

      • Saint-Paul, Bijeenkomst, 97460
        • Voltooid
        • Public mental health establishment of Reunion Island (Pôle Nord)
      • Armentières, Frankrijk, 59280
        • Voltooid
        • Public mental health establishment of Lille Metropole (59G16-G17)
      • Armentières, Frankrijk, 59280
        • Voltooid
        • Public mental health establishment of Lille Metropole (59G21)
      • Bailleul, Frankrijk, 59270
        • Voltooid
        • Flanders public mental health establishment (59G05/06)
      • Laxou, Frankrijk, 54520
        • Voltooid
        • Psychotherapeutic center of Nancy (54G02-06)
      • Lille, Frankrijk, 59000
        • Ingetrokken
        • University Hospital Center of Lille (59G08)
      • Nanterre, Frankrijk, 92014
        • Voltooid
        • Hospital Care Center of Nanterre (92G10)
      • Paris, Frankrijk, 75014
        • Voltooid
        • University Hospital Group Paris Neurosciences & Psychiatry (75G04)
      • Rouffach, Frankrijk, 68250
        • Voltooid
        • Hospital Center of Rouffach (68G02/03)
      • Rouffach, Frankrijk, 68250
        • Voltooid
        • Hospital Center of Rouffach (68G08/09)
      • Rouffach, Frankrijk, 68250
        • Voltooid
        • Hospital Center of Rouffach (Pôle LTD - 68G04/05)
      • Saint-Maurice, Frankrijk, 94410
        • Voltooid
        • Hospitals of Paris Est Val de Marne (94G01)
      • Saint-Maurice, Frankrijk, 94410
        • Voltooid
        • Hospitals of Paris Est Val de Marne (94G16)
      • Saint-Maurice, Frankrijk, 94410
        • Voltooid
        • Hospitals of Paris Est Val de Marne (Paris 11)
      • Saint-Maurice, Frankrijk, 94410
        • Voltooid
        • Hospitals of Paris Est Val de Marne (Paris 12)
      • Saint-Maurice, Frankrijk, 94410
        • Voltooid
        • Hospitals of Paris Est Val de Marne (Paris Centre)
      • Saint-Venant, Frankrijk, 62350
        • Voltooid
        • Public mental health establishment of Val de Lys Artois (62G09)
      • Saint-Venant, Frankrijk, 62350
        • Voltooid
        • Public mental health establishment of Val de Lys Artois (62G12)
      • Saint-Venant, Frankrijk, 62350
        • Voltooid
        • Public mental health establishment of Val de Lys Artois (Pôle du Ternois)
      • Étampes, Frankrijk, 91150
        • Werving
        • Barthelemy Durand public health establishment (91G05)
        • Contact:
        • Hoofdonderzoeker:
          • Amina AMRANDI, MD
      • Saint-Claude, Guadeloupe, 97122
        • Werving
        • Public mental health establishment of Guadeloupe (96G06)
        • Contact:
        • Hoofdonderzoeker:
          • Isabelle DELAROZIERE, MD
      • Saint-Claude, Guadeloupe, 97122
        • Werving
        • Public mental health establishment of Guadeloupe (96G01)
        • Contact:
        • Hoofdonderzoeker:
          • Magloire MPEMBI, MD

Deelname Criteria

Onderzoekers zoeken naar mensen die aan een bepaalde beschrijving voldoen, de zogenaamde geschiktheidscriteria. Enkele voorbeelden van deze criteria zijn iemands algemene gezondheidstoestand of eerdere behandelingen.

Geschiktheidscriteria

Leeftijden die in aanmerking komen voor studie

18 jaar en ouder (Volwassen, Oudere volwassene)

Accepteert gezonde vrijwilligers

Nee

Geslachten die in aanmerking komen voor studie

Allemaal

Beschrijving

Inclusion Criteria:

  • Regular smokers (at least one cigarette per day)
  • Followed in psychiatric ambulatory care at one of the participating sectors' CMPs
  • Adults (18 years or older)
  • Covered by the statuary health insurance
  • Who gave their informed consent to participate to the study

Exclusion Criteria:

  • Users under guardianship or legal protection,
  • Psychological state incompatible with completing the questionnaire,
  • Persons with no command or understanding of the French language

Studie plan

Dit gedeelte bevat details van het studieplan, inclusief hoe de studie is opgezet en wat de studie meet.

Hoe is de studie opgezet?

Ontwerpdetails

  • Primair doel: Preventie
  • Toewijzing: Gerandomiseerd
  • Interventioneel model: Parallelle opdracht
  • Masker: Geen (open label)

Wapens en interventies

Deelnemersgroep / Arm
Interventie / Behandeling
Experimenteel: Intervention arm

Sectors randomized to the intervention group will implement the 'Tabapsy' intervention.

The Tabapsy intervention consists in a campaign to promote smoking cessation within the CMP, and an intervention to help people stop smoking which comprises of a) A general information meeting; b) An assessment workshop, to evaluate level of dependence using validated tests and establish a personalized cessation program based on the results obtained; c) Five thematic workshops to support cessation, covering 1/ nicotine replacement treatments, electronic cigarettes and other drug treatments available for smoking cessation, 2/ emotional management, 3/ weight gain, 4/ physical activities, and 5/ manual occupations; d) Peer support groups, based on the sharing of experiences, to encourage mutual aid and solidarity between people with mental disorders who are trying to quit smoking.

The intervention relies on a facilitator specifically recruited to implement and run the intervention in the CMP. It is complemented by a website that will contain all the resources and information presented dur

Ander: Usual care

Sectors randomized to the control group will continue implementing their usual smoking cessation promotion.

Usual care corresponds to usual practices regarding smoking cessation activities in participating sectors. Those practices may vary (enquiring whether a patient is a smoker or not, offering smoking cessation if they are or only if the patient asks, etc.)

Wat meet het onderzoek?

Primaire uitkomstmaten

Uitkomstmaat
Maatregel Beschrijving
Tijdsspanne
Short-term smoking cessation
Tijdsspanne: 3 months

Short-term smoking cessation corresponds to a smoking cessation of at least 7 days, assessed among regular smoker (at least one cigarette a day) included in the study.

3 months

Secundaire uitkomstmaten

Uitkomstmaat
Maatregel Beschrijving
Tijdsspanne
Motivation to stop smoking
Tijdsspanne: 3 and 6 months

The motivation to stop smoking will be assessed using the Q-Mat ("Questionnaire de motivation à l'arrêt du tabac") scale. The computed score ranges from 0 to 20, 20 representing the highest motivation.

3 and 6 months
Voluntary quit attempts lasting at least 24 hours in the last 3 months
Tijdsspanne: 3 and 6 months

Number of voluntary quit attempts assessed both as percentage of users reporting at least one quit attempt and mean number of quit attempts per use

3 and 6 months
Voluntary quit attempts lasting at least 7 days in the last 3 months
Tijdsspanne: 3 and 6 months

Number of voluntary quit attempts assessed both as percentage of users reporting at least one quit attempt and mean number of quit attempts per user.

3 and 6 months
Tobacco consumption
Tijdsspanne: 3 and 6 months

Number of cigarettes smoked per day

3 and 6 months
Nicotine dependence
Tijdsspanne: 3 and 6 months

Nicotine dependence will be measured by the 6-question Fagerström test.

3 and 6 months
Short-term smoking cessation
Tijdsspanne: 6 months

Short-term smoking cessation corresponds to a smoking cessation of at least 7 days, assessed among regular smoker (at least one cigarette a day) included in the study.

6 months
Medium-term smoking cessation
Tijdsspanne: At 3 and 6 months

Medium-term smoking cessation corresponds to a smoking cessation of at least 30 days, assessed among regular smoker (at least one cigarette a day) included in the study.

At 3 and 6 months
Use of smoking cessation aids
Tijdsspanne: 3 and 6 months

Number of participants using smoking cessation aids (nicotine replacement therapy and other smoking cessation medications (varenicline or bupropion), electronic cigarettes, and health professionals, assessed together and separately

3 and 6 months
Level of mental well-being
Tijdsspanne: 3 and 6 months

Level of mental well-being assessed with a visual analog scale ranging from 1 to 10, 10 representing the highest level of mental well-being

3 and 6 months
Level of physical well-being
Tijdsspanne: 3 and 6 months

Level of physical well-being assessed with a visual analog scale ranging from 1 to 10, 10 representing the highest level of physical well-being

3 and 6 months
Knowledge and representations surrounding tobacco use
Tijdsspanne: 3 and 6 months

Knowledge and representations surrounding tobacco use will be assessed using a dedicated questionnaire addressed to all the included population as well as to patients who participated to a given workshop

3 and 6 months
Cost-effectiveness (short-term)
Tijdsspanne: A 6 months

Incremental cost-effectiveness ratio in cost per additional weaning of at least 7 days.

A 6 months
Cost-effectiveness (long-term)
Tijdsspanne: 6 months

Incremental cost-effectiveness ratio in cost per life-year gained over the entire life of users, using extrapolated data and economic modeling (Markov model) to assess lifetime costs and effectiveness 'till all patients in the model are deceased.

6 months
Budgetary impact (costs)
Tijdsspanne: 5 years after hypothetical generalization

Direct costs will be calculated with and without the Tabapsy intervention to assess the budgetary impact of its generalization.

5 years after hypothetical generalization
Budgetary impact (health benefits)
Tijdsspanne: 5 years after hypothetical generalization

The number of users who have stopped smoking for at least 7 days will be calculated with and without the Tabapsy intervention to assess the health gains associated with its generalization.

5 years after hypothetical generalization
Implementation
Tijdsspanne: 6 months

The implementation of the intervention and its components will be assessed using qualitative methods through semi-structured interviews conducted with 25 mental health users et 25 mental health professionnals of the intervention group).

6 months
Satisfaction level
Tijdsspanne: 3 and 6 months

Users who participated in one of the components of the intervention will be asked to rate their satisfaction using a visual analog scale ranging from 0 to 10, with 10 corresponding to the highest satisfaction.

3 and 6 months

Medewerkers en onderzoekers

Hier vindt u mensen en organisaties die betrokken zijn bij dit onderzoek.

Sponsor

Medewerkers

Onderzoekers

  • Hoofdonderzoeker: Jean-Luc ROELANDT, MD, GCS-CCOMS & INSERM ECEVE 1123
  • Studie directeur: Karine CHEVREUL, MD and Pr of public health, Evaluation and research in health services and policies for vulnerable populations, French National Institute for Health and Medical Research (INSERM ECEVE 11 23)

Studie record data

Deze datums volgen de voortgang van het onderzoeksdossier en de samenvatting van de ingediende resultaten bij ClinicalTrials.gov. Studieverslagen en gerapporteerde resultaten worden beoordeeld door de National Library of Medicine (NLM) om er zeker van te zijn dat ze voldoen aan specifieke kwaliteitscontrolenormen voordat ze op de openbare website worden geplaatst.

Bestudeer belangrijke data

Studie start (Werkelijk)

15 januari 2025

Primaire voltooiing (Werkelijk)

15 juli 2026

Studie voltooiing (Geschat)

14 november 2026

Studieregistratiedata

Eerst ingediend

18 februari 2025

Eerst ingediend dat voldeed aan de QC-criteria

7 april 2025

Eerst geplaatst (Werkelijk)

13 april 2025

Updates van studierecords

Laatste update geplaatst (Werkelijk)

8 oktober 2026

Laatste update ingediend die voldeed aan QC-criteria

7 oktober 2026

Laatst geverifieerd

1 oktober 2026

Meer informatie

Termen gerelateerd aan deze studie

Aanvullende relevante MeSH-voorwaarden

Andere studie-ID-nummers

  • 2024-A01474-43
  • A19017HS (Andere identificatie: Institute for Public Health Research (IRESP))

Plan Individuele Deelnemersgegevens (IPD)

Bent u van plan om gegevens van individuele deelnemers (IPD) te delen?

NEE

Informatie over medicijnen en apparaten, studiedocumenten

Bestudeert een door de Amerikaanse FDA gereguleerd geneesmiddel

Nee

Bestudeert een door de Amerikaanse FDA gereguleerd apparaatproduct

Nee

Deze informatie is zonder wijzigingen rechtstreeks van de website clinicaltrials.gov gehaald. Als u verzoeken heeft om uw onderzoeksgegevens te wijzigen, te verwijderen of bij te werken, neem dan contact op met register@clinicaltrials.gov. Zodra er een wijziging wordt doorgevoerd op clinicaltrials.gov, wordt deze ook automatisch bijgewerkt op onze website .

Abonneren